NCI-60 whole exome sequencing and pharmacological cellminer analyses

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Reinhold, William C ^a   Varma, Sudhir ^a,b   Sousa, Fabricio ^a,c   Sunshine, Margot ^a,d   Abaan, Ogan D ^a   Davis, Sean R ^a   Reinhold, Spencer W ^a   Kohn, Kurt W ^a   Morris, Joel ^a   Meltzer, Paul S ^a   Doroshow, James H ^a   Pommier, Yves ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b HiThru Analytics LLC   (United States)

^c FEDERAL UNIVERSITY OF MATO GROSSO DO SUL   (Brazil)

^d GENERAL DYNAMICS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 (2 DIMETHYLAMINOETHYL) 9 METHOXY 5 NITROPYRAZOLO[3,4,5 KL]ACRIDINE; 5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; B RAF KINASE; CARMUSTINE; CHELERYTHRINE; CLADRIBINE; CLOFARABINE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; EVEROLIMUS; FLUDARABINE PHOSPHATE; FOSTAMATINIB; HYPOTHEMYCIN; IFOSFAMIDE; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE; RAD52 PROTEIN; RETINOIC ACID; SIMVASTATIN; SOMATOMEDIN; SOMATOMEDIN B RECEPTOR; STAT2 PROTEIN; SUNITINIB; TUBERIN; UNINDEXED DRUG; URAMUSTINE; VEMURAFENIB; ANTINEOPLASTIC AGENT;

ARTICLE; CANCER CELL; CANCER GROWTH; DRUG ACTIVITY; EXOME; GENE; GENE SEQUENCE; GENETIC IDENTIFICATION; GENETIC VARIABILITY; HUMAN; NOM1 GENE; NUCLEOTIDE SEQUENCE; TLL2 GENE; XDH GENE; BIOLOGY; DATA MINING; DNA SEQUENCE; FACTUAL DATABASE; GENETICS; GENOME; GENOMICS; NEOPLASMS; PROCEDURES; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BASE SEQUENCE; CELL LINE, TUMOR; COMPUTATIONAL BIOLOGY; DATA MINING; DATABASES, FACTUAL; EXOME; GENETIC VARIATION; GENOME; GENOMICS; HUMANS; NEOPLASMS; SEQUENCE ANALYSIS, DNA;

EID: 84904490528     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0101670     Document Type: Article

References (71)

1. Dyment DA, Cader MZ, Chao MJ, Lincoln MR, Morrison KM, et al. (2012) Exome sequencing identifies a novel, multiple sclerosis susceptibility variant in the TYK2 gene. Neurology.
2. Doherty D, Bamshad MJ (2012) Exome sequencing to find rare variants causing neurologic diseases. Neurology.
3. Moldovan F, Patten SA, Fendri K, Girard S, Zaouter C, et al. (2012) Exome sequencing identifies novel candidate mutations in idiopathic. Stud Health Technol Inform 176: 453.
4. Choi BO, Koo SK, Park MH, Rhee H, Yang SJ, et al. (2012) Exome sequencing is an efficient tool for genetic screening of Charcot-Marie-Tooth Disease. Hum Mutat.
5. Johnston JJ, Rubinstein WS, Facio FM, Ng D, Singh LN, et al. (2012) Secondary Variants in Individuals Undergoing Exome Sequencing: Screening of 572 Individuals Identifies High-Penetrance Mutations in Cancer-Susceptibility Genes. Am J Hum Genet.
6. Koo GC, Tan SY, Tang T, Poon SL, Allen GE, et al. (2012) Janus Kinase 3-Activating Mutations Identified in Natural Killer/T-cell Lymphoma. Cancer Discov.
7. Banerji S, Cibulskis K, Rangel-Escareno C, Brown KK, Carter SL, et al. (2012) Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 486: 405-409.
8. Cromer MK, Starker LF, Choi M, Udelsman R, Nelson-Williams C, et al. (2012) Identification of Somatic Mutations in Parathyroid Tumors Using Whole-Exome Sequencing. J Clin Endocrinol Metab.
9. Hertz DL (2013) Germline pharmacogenetics of paclitaxel for cancer treatment. Pharmacogenomics 14: 1065-1084.
10. Gillis N, Patel J, Innocenti F (2013) Clinical Implementation of Germ Line Cancer Pharmacogenetic Variants During the Next-Generation Sequencing Era. Clin Pharmacol Ther.
11. Abaan OD, Polley EC, Davis SR, Zhu YJ, Bilke S, et al. (2013) The Exomes of the NCI-60 Panel: A Genomic Resource for Cancer Biology and Systems Pharmacology. Cancer Research 73: 4372-4382.
12. Cronin M, Ross JS (2011) Comprehensive next-generation cancer genome sequencing in the era of targeted therapy and personalized oncology. Biomark Med 5: 293-305.
13. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, et al. (2012) The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483: 603-607.
14. Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, et al. (2012) Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483: 570-575.
15. Reinhold WC, Sunshine M, Liu H, Varma S, Kohn KW, et al. (2012) CellMiner: A Web-Based Suite of Genomic and Pharmacologic Tools to Explore Transcript and Drug Patterns in the NCI-60 Cell Line Set. Cancer Res.
16. Weinstein JN (2012) Drug discovery: Cell lines battle cancer. Nature 483: 544-545.
17. Paull K, Shoemaker R, Hodes L, Monks A, Scudiero D, et al. (1989) Display and analysis of patterns of differential activity of drugs against human tumor cell lines: Development of mean graph and COMPARE algorithm. J Natl Cancer Inst 81: 1088-1092. (Pubitemid 19175145)
18. Shoemaker RH (2006) The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 6: 813-823.
19. Holbeck SL, Collins JM, Doroshow JH (2010) Analysis of Food and Drug Administration-approved anticancer agents in the NCI60 panel of human tumor cell lines. Mol Cancer Ther 9: 1451-1460.
20. Developmental Therapeutics Program (DTP) website. http://dtp.nci.nih.gov/ . Accessed 2012 Aug 15.
21. Ikediobi O, Davies H, Bignell G, Edkins S, Stevens C, et al. (2006) Mutation analysis of twenty-four known cancer genes in the NCI-60 cell line set. Mol Cancer Ther 5: 2606-2612. (Pubitemid 44848987)
22. Liu H, D'Andrade P, Fulmer-Smentek S, Lorenzi P, Kohn K, et al. (2010) mRNA and microRNA expression profiles integrated with drug sensitivities of the NCI-60 human cancer cell lines MCT 9(5):1080-1091.
23. CellMiner website. http://discover.nci.nih.gov/cellminer/. Accessed 2013 May 13.
24. Ingenuity Systems website. http://www.ingenuity.com/NCI60-WES.: Accessed 2012 July 20.
25. Cancer Cell Line Encyclopedia (CCLE) website. http://www.broadinstitute. org/software/cprg/?q=node/11.: Accessed 2012 July 27.
26. Genomics of Drug Sensitivity project (GDS) website. http://www. cancerrxgene.org.: Accessed 2012 Feb 10.
27. Roschke A, Tonon G, Gehlhaus K, McTyre N, Bussey K, et al. (2003) Karyotypic Complexity of the NCI-60 Drug-Screening Panel. Cancer Research 63: 8634-8647. (Pubitemid 38064038)
28. Bussey KJ, Chin K, Lababidi S, Reimers M, Reinhold WC, et al. (2006) Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel. Mol Cancer Ther 5: 853-867. (Pubitemid 43724584)
29. NCBI GEO website, Agilent-012750 Human Genome CGH Microarray 44A. http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GPL2873.: Accessed 2012 Feb 23.
30. Varma S, Pommier Y, Sunshine M, Weinstein JN, Reinhold WC (2014) High resolution copy number variation data in 1 the NCI-60 cancer cell 2 lines from whole genome microarrays accessible through CellMiner. PLoS One 9: e92047.
31. Reinhold WC, Mergny JL, Liu H, Ryan M, Pfister TD, et al. (2010) Exon array analyses across the NCI-60 reveal potential regulation of TOP1 by transcription pausing at guanosine quartets in the first intron. Cancer Res 70: 2191-2203.
32. Ruan X, Kocher JP, Pommier Y, Liu H, Reinhold WC (2012) Mass Homozygotes Accumulation in the NCI-60 Cancer Cell Lines As Compared to HapMap Trios, and Relation to Fragile Site Location. PLoS One 7: e31628.
33. Lorenzi P, Reinhold W, Varma S, Hutchinson A, Pommier Y, et al. (2009) DNA fingerprinting of the NCI-60 cell line panel. Mol Cancer Ther 8: 713-724.
34. Blower PE, Verducci JS, Lin S ZJ, Chung JH, Dai Z, et al. (2007) MicroRNA expression profiles for the NCI-60 cancer cell panel. Mol Cancer Ther May;6(5):1483-91.
35. Nishizuka S, Charboneau L, Young L, Major S, Reinhold W, et al. (2003) Proteomic profiling of the NCI60 cancer cell lines using new high-density 'reverse-phase' lysate microarrays. Proc Natl Acad Sci U S A 100: 14229-14234. (Pubitemid 37499219)
36. Moghaddas Gholami A, Hahne H, Wu Z, Auer FJ, Meng C, et al. (2013) Global proteome analysis of the NCI-60 cell line panel. Cell Rep 4: 609-620.
37. Jain M, Nilsson R, Sharma S, Madhusudhan N, Kitami T, et al. (2012) Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation. Science 336: 1040-1044.
38. Stuelten CH, Mertins SD, Busch JI, Gowens M, Scudiero DA, et al. (2010) Complex display of putative tumor stem cell markers in the NCI60 tumor cell line panel. Stem Cells 28: 649-660.
39. Adams S, Robbins FM, Chen D, Wagage D, Holbeck SL, et al. (2005) HLA class I and II genotype of the NCI-60 cell lines. J Transl Med 3: 11.
40. Holbeck S, Chang J, Best AM, Bookout AL, Mangelsdorf DJ, et al. (2010) Expression profiling of nuclear receptors in the NCI60 cancer cell panel reveals receptor-drug and receptor-gene interactions. Mol Endocrinol 24: 1287-1296.
41. Szakacs G, Annereau J, Lababidi S, Shankavaram U, Arciello A, et al. (2004) Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. Cancer Cell Aug;6(2):129-37.
42. Amundson SA, Do KT, Vinikoor LC, Lee RA, Koch-Paiz CA, et al. (2008) Integrating global gene expression and radiation survival parameters across the 60 cell lines of the National Cancer Institute Anticancer Drug Screen. Cancer Res 68: 415-424. (Pubitemid 351380067)
43. Stults DM, Killen MW, Shelton BJ, Pierce AJ (2011) Recombination phenotypes of the NCI-60 collection of human cancer cells. BMC Mol Biol 12: 23.
44. Algeciras-Schimnich A, Pietras EM, Barnhart BC, Legembre P, Vijayan S, et al. (2003) Two CD95 tumor classes with different sensitivities to antitumor drugs. Proc Natl Acad Sci U S A 100: 11445-11450. (Pubitemid 37205955)
45. Garner KM, Eastman A (2011) Variations in Mre11/Rad50/Nbs1 status and DNA damage-induced S-phase arrest in the cell lines of the NCI60 panel. BMC Cancer 11: 206: 201-213.
46. Lee JS, Paull K, Alvarez M, Hose C, Monks A, et al. (1994) Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen. Mol Pharmacol 46: 627-638. (Pubitemid 24334752)
47. Genomes website. http://www.1000genomes.org/. Accessed 2012 Jun 11.
48. NHLBI Exome Sequencing Project (ESP) website. http://evs.gs.washington. edu/EVS/. Accessed 2012 Jan 24.
49. Sorting Intolerant From Tolerant (SIFT) website. http://sift.bii.a-star. edu.sg/. Accessed 2012 March 17.
50. PollyPhen-2 website. http://genetics.bwh.harvard.edu/pph2/. Accessed 2012 Feb 17.
51. COSMIC website. http://www.sanger.ac.uk/genetics/CGP/cosmic/: Accessed 2012 March 26.
52. Annovar website. http://www.openbioinformatics.org/annovar/. Accessed 2012 July 17.
53. dbSNP website. http://www.ncbi.nlm.nih.gov/projects/SNP/. Accessed 2012 Feb 17.
54. NCBI website. http://www.ncbi.nlm.nih.gov/. Accessed 2012 May 14.
55. Rubinstein LV, Shoemaker RH, Paull KD, Simon RM, Tosini S, et al. (1990) Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J Natl Cancer Inst 82: 1113-1118. (Pubitemid 20213251)
56. Kent WJ (2002) BLAT - the BLAST-like alignment tool. Genome Res 12: 656-664.
57. Cancer Genome Project (CGP) website. http://wwwsangeracuk/research/ projects/cancergenome/ Accessed 2012 Jan 10.
58. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Jr., et al. (2013) Cancer genome landscapes. Science 339: 1546-1558.
59. DoublingTimes website. http://dtp.nci.nih.gov/docs/misc/common-files/ cell-list.html: Accessed 2012 Jan 15.
60. Fishers Exact Test website. wwwlangsrudcom/fisherhtm Accessed 2012, Jan 10.
61. Gao R, Das B, Chatterjee R, Abaan OD, Agama K, et al. (2013) Epigenetic and genetic inactivation of tyrosyl-DNA-phosphodiesterase 1 (TDP1) in human lung cancer cells from the NCI-60 panel. DNA Repair In press.
62. Tanaka H, Nishida K, Sugita K, Yoshioka T (1999) Antitumor efficacy of hypothemycin, a new Ras-signaling inhibitor. Jpn J Cancer Res 90: 1139-1145.
63. Patrawala S, Puzanov I (2012) Vemurafenib (RG67204, PLX4032): a potent, selective BRAF kinase inhibitor. Future Oncol 8: 509-523.
64. King AJ, Patrick DR, Batorsky RS, Ho ML, Do HT, et al. (2006) Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885. Cancer Res 66: 11100-11105. (Pubitemid 46009933)
65. Wozniak RJ, Klimecki WT, Lau SS, Feinstein Y, Futscher BW (2007) 5-Aza-2′-deoxycytidine-mediated reductions in G9A histone methyltransferase and histone H3 K9 di-methylation levels are linked to tumor suppressor gene reactivation. Oncogene 26: 77-90. (Pubitemid 46067333)
66. Sell C, Baserga R, Rubin R (1995) Insulin-like growth factor I (IGF-I) and the IGF-I receptor prevent etoposide-induced apoptosis. Cancer Res 55: 303-306.
67. Uluer ET, Aydemir I, Inan S, Ozbilgin K, Vatansever HS (2011) Effects of 5-fluorouracil and gemcitabine on a breast cancer cell line (MCF-7) via the JAK/STAT pathway. Acta Histochem.
68. Drablos F, Feyzi E, Aas PA, Vaagbo CB, Kavli B, et al. (2004) Alkylation damage in DNA and RNA-repair mechanisms and medical significance. DNA Repair (Amst) 3: 1389-1407. (Pubitemid 39221738)
69. Gmeiner WH, Reinhold WC, Pommier Y (2010) Genome-wide mRNA and microRNA profiling of the NCI 60 cell-line screen and comparison of FdUMP[10] with fluorouracil, floxuridine, and topoisomerase 1 poisons. Mol Cancer Ther 9: 3105-3114.
70. Zoppoli G, Regairaz M, Leo E, Reinhold WC, Varma S, et al. (2012) Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents. Proc Natl Acad Sci U S A 109: 15030-15035.
71. Cunningham L, Finckbeiner S, Hyde RK, Southall N, Marugan J, et al. (2012) Identification of benzodiazepine Ro5-3335 as an inhibitor of CBF leukemia through quantitative high throughput screen against RUNX1-CBFbeta interaction. Proc Natl Acad Sci U S A 109: 14592-14597.